Memorial Sloan Kettering Cancer Center
‘Global problem’: Numerous factors, biases contribute to overtreatment at end of life
Nathan I. Cherny, MD, has worked all around the world.
Zenocutuzumab exhibits efficacy in NRG1 fusion-positive cancers
Zenocutuzumab exhibited efficacy among patients with NRG1 fusion-positive cancers, according to phase 2 data published in The New England Journal of Medicine.
Memorial Sloan Kettering names hematologic malignancies division head
Ivan Maillard, MD, PhD, has been appointed head of the division of hematologic malignancies at Memorial Sloan Kettering Cancer Center.
‘Wake-up call’: Cancer cachexia causes worse outcomes after CAR-T for lymphoma
Historically, Jae H. Park, MD, has not paid much attention to his patients’ weight loss.
Imlunestrant alone, with abemaciclib delays progression of advanced breast cancer
SAN ANTONIO — Imlunestrant alone or as part of combination therapy extended PFS for certain patients with advanced breast cancer resistant to hormone therapy, according to study results presented at San Antonio Breast Cancer Symposium.
High-fiber diet may slow progression of precursor conditions to multiple myeloma
SAN DIEGO — A high-fiber plant-based diet may delay progression of certain precursor conditions to multiple myeloma, according to study results presented at ASH Annual Meeting and Exposition.
More than half of children with cancer die in the hospital
Children with cancer more often died at home less often than adults, according to study results.
Person-centered language in oncology helps people ‘feel genuinely cared for’
When referring to individuals with cancer, emphasizing the person rather than the condition improves patient morale and refocuses clinicians on the mission of patient-centered care, according to an opinion paper published in JAMA Oncology.
Shorter course of radiation after mastectomy does not compromise breast reconstruction
Women who want breast reconstruction after mastectomy can undergo a shorter radiation therapy regimen without significantly increasing their risk for complications, according to results of a randomized phase 3 trial.
Risk for second primary malignancies no greater with CAR-T than other standard therapies
Patients who received chimeric antigen receptor T-cell therapy did not exhibit increased risk for second primary malignancies compared with those who received other standard treatments, according to a systematic review and meta-analysis.